Gemcitabine
Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a monoclonal antibody, which targets and restricts proteins that stimulate blood vessel growth in tumors. The Lancet Oncology published the results of the Italian study involving…
Using maintenance therapy with gemcitabine alongside chemotherapy can help increase survival in patients compared to patients just receiving palliative care. Gemcitabine is an antimetabolite, which prevents cancer cells from dividing into new cancer cells. Chemotherapy is usually the first line treatment for mesothelioma, and if patients are able to receive surgery, it is used as…
Mesothelioma is a deadly cancer of the mesothelium, which lines the lungs, heart, abdomen, and tunica vaginalis testis after exposure to asbestos. The most common type is pleural mesothelioma, which affects the lining of the lungs. There is no cure, so the best option for people with this cancer is undergoing clinical trials that help…
A Phase III clinical trial is now underway in the pivotal study of interferon alfa-2b gene therapy in pleural mesothelioma. After promising results from the Phase II clinical trial, scientists and researchers are hopeful they are just one step away from FDA approval for this cancer treatment that is over 20 years in the making.…
